Kestra Medical Technologies (NASDAQ:KMTS) Upgraded at Wall Street Zen

Kestra Medical Technologies (NASDAQ:KMTS) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts have also weighed in on KMTS. BTIG Research reaffirmed a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. The Goldman Sachs Group reduced their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $27.40.

Kestra Medical Technologies Stock Up 17.1%

Shares of NASDAQ:KMTS opened at $26.43 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The business’s 50 day simple moving average is $21.05 and its two-hundred day simple moving average is $22.78. The firm has a market cap of $1.54 billion, a P/E ratio of -6.67 and a beta of 0.83.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the sale, the insider directly owned 395,467 shares of the company’s stock, valued at approximately $8,229,668.27. The trade was a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 45,000 shares of company stock worth $927,150. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Seven Grand Managers LLC bought a new stake in Kestra Medical Technologies in the 4th quarter worth about $2,652,000. Summit Partners Public Asset Management LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $9,282,000. Eventide Asset Management LLC boosted its stake in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Kestra Medical Technologies by 15.0% in the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after buying an additional 28,573 shares during the last quarter. Finally, UBS Group AG grew its holdings in shares of Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after acquiring an additional 69,908 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.